A cohort study of the risk of cancer associated with type 2 diabetes

Citation for published version:
Ogunleye, AA, Ogston, SA, Morris, AD & Evans, JMM 2009, 'A cohort study of the risk of cancer associated with type 2 diabetes' British Journal of Cancer, vol 101, no. 7, pp. 1199-1201. DOI: 10.1038/sj.bjc.6605240

Digital Object Identifier (DOI):
10.1038/sj.bjc.6605240

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
British Journal of Cancer

Publisher Rights Statement:
Available under a Creative Commons license (CC-BY-NC-SA)

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Short Communication

A cohort study of the risk of cancer associated with type 2 diabetes

AA Ogunleye, SA Ogston, AD Morris, JMM Evans*

1Section of Public Health, Division of Clinical and Population Sciences and Education, University of Dundee, Mackenzie Building, Kirsty Semple Way, Dundee DD2 4BF, Scotland, UK; 2Diabetes Research Centre, University of Dundee, Ninewells Hospital, Dundee DD1 9SY, Scotland, UK

BACKGROUND: There is evidence to suggest that diabetes may increase the risk of incidence and mortality from cancer.

METHODS: In a cohort study using record-linkage health-care datasets for Tayside, Scotland in 1993–2004, we followed up 9577 newly diagnosed patients with type 2 diabetes, and two matched non-diabetic comparators, in the national cancer register.

RESULTS AND CONCLUSIONS: The risk ratio for any cancer, adjusted for deprivation, was 0.99 (95%CI 0.90–1.09). Significantly increased risks were observed for pancreatic, liver and colon cancer.

British Journal of Cancer (2009) 101, 1199–1201. doi:10.1038/sj.bjc.6605240 www.bjcancer.com

Published online 18 August 2009

Keywords: type 2 diabetes; cohort study; survival analysis; epidemiology.

Whether there was an increased prevalence of cancer associated with insulin use was questioned in the early twentieth century (Marble, 1934), and there is a growing body of evidence suggesting that diabetes increases the risk of the incidence and mortality from certain cancers. These include pancreatic and liver cancer, colorectal cancer, breast cancer, bladder cancer, cancer of the kidney and endometrial cancer (Wideroff et al, 1997; Coughlin et al, 2004; Rousseau et al, 2006; Kuriki et al, 2007). However, the results of studies of diabetes and cancer have been very mixed with many not distinguishing between type 1 and type 2 diabetes (Wideroff et al, 1997), or have defined groups according to treatment (Swerdlow et al, 2005). In some studies, the basis for diabetes diagnosis is self-report (Coughlin et al, 2004), in others it is clinical (Saydah et al, 2003). Studies have been both retrospective (Kuriki et al, 2007) and prospective, with some prospective studies following up from diagnosis of diabetes (Ragozzino et al, 1982); another followed up a cross-sectional sample of patients (Swerdlow et al, 2005). In this study, we present the risks of different cancers following diagnosis of type 2 diabetes in Tayside, Scotland, using a standardised methodology.

MATERIALS AND METHODS

This cohort study was carried out using the datasets of the Health Informatics Centre (HIC), University of Dundee, which developed the record linkage of routinely collected health-care datasets to facilitate epidemiological and other health research in the population of Tayside Health Board, Scotland (approximately population 400 000) (Evans et al, 1995). A diabetes clinical information system was used to identify all patients registered with any Tayside GP practice who were diagnosed with type 2 diabetes in 1993–2004 (Morris et al, 1997). Their date of diagnosis was defined as their study index date. Any patient who had an earlier record of cancer diagnosis on the Scottish national cancer registry (SMR6) was excluded (Scottish Cancer Registry, 2009).

For each eligible patient with type 2 diabetes, two non-diabetic comparators were selected at random from computerised lists of patients registered with primary care, matched for age (within 1 year), sex and GP practice. The index date of the comparator was that of its matched diabetic patient; and the comparator had to be alive and have no earlier cancer diagnosis on this date.

Diabetic patients and their comparators were followed for a maximum of 11 years in a survival analysis to the study end date (1st January 2004). The primary outcome was diagnosis of malignant cancer on SMR6; deaths were also identified. The relationship between type 2 diabetes and cancer was assessed in a Cox regression unadjusted, and then in a multivariable model adjusted for deprivation (measured using deciles of a postcode score for material deprivation) (Carstairs, 1990). This was repeated for specific cancer types according to the ICD10 diagnosis code recorded on SMR6.

Statistical analyses were performed using SPSS (Statistical Package for Social Scientist) 15.0 software programme. All data were anonymised for analysis. Ethical approval was obtained from the Multi-Centre Research and Ethics Committee for Scotland.

RESULTS

The study population comprised 9577 people registered with any Tayside general practice diagnosed with type 2 diabetes between 1993 and 2004, and 19 154 non-diabetic comparators, of these, 53.3% were male, and the mean age at index date was 62 years; 661 (6.9%) of patients with diabetes were diagnosed with cancer, as recorded on SMR6, during follow-up (mean length of follow-up
DISCUSSION

This study finds no evidence that patients with type 2 diabetes have an overall increased risk of cancer compared with non-diabetic people, with adjusted risk ratios approaching unity. However, there was an increased risk of certain specific cancers that, because uncommon, did not have a substantial effect on the overall risk ratio.

Patients with type 2 diabetes were three times more likely to develop pancreatic cancer than non-diabetic people, a widely reported association (Coughlin et al, 2004; Rousseau et al, 2006; Kuriki et al, 2007). Although type 2 diabetes could be a risk factor for pancreatic cancer (Wideroff et al, 1997), it is more likely to be a consequence (reverse causality) (Gullo et al, 1994), being stronger among recently diagnosed patients. The three-fold increased risk of liver cancer is also similar to earlier reports (Wideroff et al, 1997; Rousseau et al, 2006), some of which have adjusted for confounding by alcohol and viral hepatitis (Davila et al, 2005).

However, the risk is higher after excluding patients diagnosed in the year following diabetes, suggesting that reverse causality is unlikely to be the explanation here.

Our slight increased risk of 1.46 for cancer of the colon is in line with a recent meta-analysis (Larsson et al, 2005). Other studies have observed similar risks, some of which were not significant perhaps owing to small sample size (Wideroff et al, 1997; Coughlin et al, 2004; Rousseau et al, 2006). In contrast, we observed no increased risk for rectal cancer, consistent with the lack of statistically significant increased risk in the Nurses' Health Study (Hu et al, 1999).

This study provided no evidence for associations between type 2 diabetes and other cancer types. A Danish study found increased risks of kidney and endometrial cancer (Wideroff et al, 1997), these cancers were not common in our cohort and larger sample sizes would be needed to detect an associated risk. We also found no increase of breast or bladder cancer, despite a US finding of excess mortality (Coughlin et al, 2004). However, associations with mortality could be confounded by survival-related factors.

We are confident in the validity of our data sources, which have been widely used in epidemiological studies, whereas SMR6 is a national, validated dataset. It also allowed estimation of risks of cancer incidence, using precise dates of diagnosis. The study's main limitation was lack of information on lifestyle-related confounders, although we were able to adjust for deprivation.

Patients with diabetes may have a higher prevalence of lifestyle-related risk factors for cancer, such as obesity (Hjartaker et al, 2008). However, we found no increased risks of many cancers despite these potential confounders, thereby increasing confidence in the conclusions.

REFERENCES

Carstairs V (1990) Deprivation and health in Scotland. Health Bull (Edinb) 48: 162 – 175
Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159: 1160 – 1167
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case-control study. Gut 54: 553 – 559
Evans JMM, McDevitt DG, MacDonald TM (1995) The Tayside Medicines Monitoring Unit (MEMO): a record-linkage system for pharmacovigilance. Pharm Med 9: 177 – 184
Gullo L, Pezzilli R, Morselli-Labate AM (1994) Diabetes and the risk of pancreatic cancer. N Engl J Med 331: 81 – 84
Hjartaker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics: cancer repercussions. Adv Exp Med Biol 630: 72 – 93

Table 1 Unadjusted and adjusted risk ratios for any malignant cancer and specific cancers among patients with type 2 diabetic people and their comparators in Tayside, Scotland, 1993–2004

| No (%) of cancer (diabetes) | No (%) of cancer (comparators) | Unadjusted RR (95% CI) | Adjusted RR (95% CI)* | Adjusted RR (95% CI) (excluding outcomes in 1st year) |
|-----------------------------|-------------------------------|------------------------|-----------------------|--------------------------------------------------------|
| Any malignant cancer C00–97 | 661 (6.9%)                    | 1364 (7.1%)            | 1.01 (0.92 – 1.11)    | 0.99 (0.90 – 1.09)                                     |
| Skin C43–44                  | 128 (1.3%)                    | 322 (1.7%)             | 0.83 (0.68 – 1.02)    | 0.84 (0.68 – 1.03)                                     |
| Lung C33–34                  | 77 (0.8%)                     | 198 (1.0%)             | 0.81 (0.62 – 1.05)    | 0.77 (0.59 – 1.01)                                     |
| Colon C18–19                 | 67 (0.7%)                     | 95 (0.5%)              | 1.49 (1.09 – 2.03)    | 1.46 (1.07 – 2.01)                                     |
| Breast C50                   | 52 (0.5%)                     | 103 (0.5%)             | 1.05 (0.76 – 1.47)    | 1.05 (0.75 – 1.47)                                     |
| Prostate C61                 | 43 (0.4%)                     | 117 (0.6%)             | 0.77 (0.54 – 1.09)    | 0.77 (0.54 – 1.09)                                     |
| Pancreas C25                 | 31 (0.3%)                     | 20 (0.1%)              | 3.19 (1.82 – 5.60)    | 3.06 (1.73 – 5.39)                                     |
| Oesophagus C15               | 24 (0.3%)                     | 28 (0.1%)              | 1.79 (1.04 – 3.08)    | 1.70 (0.98 – 2.95)                                     |
| Bladder C67                  | 17 (0.2%)                     | 51 (0.3%)              | 0.69 (0.40 – 1.20)    | 0.70 (0.40 – 1.21)                                     |
| Non-Hodgkins C82–85          | 17 (0.2%)                     | 26 (0.1%)              | 1.37 (0.74 – 2.51)    | 1.36 (0.74 – 2.51)                                     |
| Liver C22                    | 17 (0.2%)                     | 12 (0.1%)              | 2.96 (1.41 – 6.19)    | 2.93 (1.40 – 6.14)                                     |
| Stomach C16                  | 16 (0.2%)                     | 46 (0.2%)              | 0.73 (0.41 – 1.29)    | 0.73 (0.41 – 1.29)                                     |
| Rectum C20                   | 13 (0.1%)                     | 48 (0.3%)              | 0.57 (0.31 – 1.06)    | 0.56 (0.30 – 1.03)                                     |
| Endometrium C54              | 13 (0.1%)                     | 17 (0.1%)              | 1.60 (0.78 – 3.29)    | 1.47 (0.70 – 3.09)                                     |
| Kidney C64                   | 6 (0.1%)                      | 24 (0.1%)              | 0.52 (0.21 – 1.28)    | 0.52 (0.21 – 1.27)                                     |

Abbreviations: CI = confidence intervals; RR = risk ratio. *Adjusted for deprivation decile.
Hu FB, Manson J.E, Hunter D, Colditz GA, Michels KB (1999) Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. *J Natl Cancer Inst* 91: 542–547
Kuriki K, Hirose K, Tajima K (2007) Diabetes and cancer risk for all specific sites among Japanese men and women. *Eur J Cancer Prev* 7: 89–107
Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. *J Natl Cancer Inst* 97: 1679–1687
Marble A (1934) Diabetes and cancer. *New Engl J Med* 211: 339–349
Morris AD, Boyle DIR, MacAlpine R, Emelie-Smith A, Jung RT, Newton RW, MacDonald TM for the DARTS/MEMO Collaboration (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record-linkage to create a diabetes register. *Br Med J* 315: 524–528
Ragozzino M, Melton III LJ, Chu CP, Palumbo PJ (1982) Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. *J Chron Dis* 35: 13–19
Rousseau MC, Parent ME, Pollak MN, Siemiatycki J (2006) Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. *Int J Cancer* 118: 2105–2109
Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and risk of cancer death in the United States. *Am J Epidemiol* 157: 1092–1100
Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, Waugh NR, Morris AD, Gulling W, Gale EA, Patterson CC, Keen H (2005) Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. *Br J Cancer* 69: 2070–2075
The Scottish Cancer Registry. http://www.isdscotland.org/isd/3535.html. Accessed online 24th February 2009
Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S (1997) Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* 89: 1360–1365

Type 2 diabetes and risk of cancer
AA Ogunleye et al

© 2009 Cancer Research UK

British Journal of Cancer (2009) 101(7), 1199 – 1201

Epidemiology